TNFA TNF Pharmaceuticals Inc.
Price (delayed)
$1.51
Market cap
$3.58M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$10.81
Enterprise value
$3.07M
mymd is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. mymd-1 is a drug platform based on a clinical stage
Highlights
The company's debt has shrunk by 76% YoY and by 28% QoQ
TNF Pharmaceuticals's equity has shrunk by 99% YoY and by 99% QoQ
The quick ratio has shrunk by 53% YoY
Key stats
What are the main financial stats of TNFA
Market
Valuations
Earnings
Shares outstanding
2.37M
Market cap
$3.58M
Enterprise value
$3.07M
Price to earnings (P/E)
N/A
Price to book (P/B)
35.63
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$17.69M
EBITDA
-$17.69M
Free cash flow
-$9.67M
Per share
Balance sheet
Liquidity
EPS
-$10.81
Free cash flow per share
-$4.25
Book value per share
$0.04
Revenue per share
$0
TBVPS
$6.98
Total assets
$26.38M
Total liabilities
$26M
Debt
$25,803
Equity
$97,805
Working capital
$8.57M
Debt to equity
0.26
Current ratio
2.48
Quick ratio
2.26
Net debt/EBITDA
0.03
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-115.9%
Return on equity
-246.4%
Return on invested capital
-484.8%
Return on capital employed
-85.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TNFA stock price
How has the TNF Pharmaceuticals stock price performed over time
Intraday
-3.21%
1 week
-9.04%
1 month
-13.71%
1 year
-93.11%
YTD
-80.54%
QTD
-17.93%
Financial performance
How have TNF Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$14.91M
Net income
-$17.69M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 44% QoQ and by 35% YoY
TNFA's operating income is up by 14% since the previous quarter
Growth
What is TNF Pharmaceuticals's growth rate over time
Valuation
What is TNF Pharmaceuticals stock price valuation
P/E
N/A
P/B
35.63
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 14% from the previous quarter and by 10% YoY
TNF Pharmaceuticals's equity has shrunk by 99% YoY and by 99% QoQ
Efficiency
How efficient is TNF Pharmaceuticals business performance
TNF Pharmaceuticals's return on equity has shrunk by 157% YoY and by 70% QoQ
The ROA has plunged by 94% YoY and by 31% from the previous quarter
TNFA's ROIC has dropped by 71% since the previous quarter
Dividends
What is TNFA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TNFA.
Financial health
How did TNF Pharmaceuticals financials performed over time
The total liabilities has soared by 89% YoY
The total assets has soared by 82% from the previous quarter and by 4.5% YoY
The company's debt is 74% lower than its equity
TNF Pharmaceuticals's equity has shrunk by 99% YoY and by 99% QoQ
The company's debt has shrunk by 76% YoY and by 28% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.